A detailed history of Israel Englander (Millennium Management LLC) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 499,300 shares of ITCI stock, worth $43 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
499,300
Previous 889,102 43.84%
Holding current value
$43 Million
Previous $60.9 Million 40.05%
% of portfolio
0.02%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $26.5 Million - $31.5 Million
-389,802 Reduced 43.84%
499,300 $36.5 Million
Q2 2024

Aug 14, 2024

BUY
$64.76 - $79.84 $39.3 Million - $48.4 Million
606,358 Added 214.45%
889,102 $60.9 Million
Q1 2024

May 15, 2024

SELL
$64.37 - $75.65 $5.84 Million - $6.87 Million
-90,761 Reduced 24.3%
282,744 $19.6 Million
Q4 2023

Feb 14, 2024

SELL
$46.37 - $73.65 $12 Million - $19.1 Million
-259,409 Reduced 40.99%
373,505 $26.8 Million
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $7.35 Million - $8.94 Million
134,526 Added 26.99%
632,914 $40.1 Million
Q1 2023

May 15, 2023

SELL
$43.8 - $56.99 $39.3 Million - $51.2 Million
-898,232 Reduced 64.31%
498,388 $27 Million
Q4 2022

Feb 14, 2023

SELL
$44.07 - $54.45 $19.6 Million - $24.2 Million
-444,429 Reduced 24.14%
1,396,620 $73.9 Million
Q3 2022

Nov 14, 2022

BUY
$42.7 - $59.99 $34.3 Million - $48.2 Million
803,772 Added 77.49%
1,841,049 $85.7 Million
Q2 2022

Aug 15, 2022

BUY
$43.0 - $65.64 $13.4 Million - $20.5 Million
311,808 Added 42.98%
1,037,277 $59.2 Million
Q1 2022

May 16, 2022

BUY
$38.74 - $62.09 $3.58 Million - $5.73 Million
92,312 Added 14.58%
725,469 $44.4 Million
Q4 2021

Feb 14, 2022

SELL
$35.2 - $53.42 $3.66 Million - $5.56 Million
-103,994 Reduced 14.11%
633,157 $33.1 Million
Q3 2021

Nov 15, 2021

BUY
$28.72 - $42.49 $2.7 Million - $4 Million
94,173 Added 14.65%
737,151 $27.5 Million
Q2 2021

Aug 16, 2021

SELL
$29.3 - $44.5 $4.54 Million - $6.9 Million
-155,074 Reduced 19.43%
642,978 $26.2 Million
Q1 2021

May 17, 2021

SELL
$30.8 - $39.51 $24.5 Million - $31.5 Million
-796,101 Reduced 49.94%
798,052 $27.1 Million
Q4 2020

Feb 16, 2021

SELL
$23.34 - $32.22 $9.38 Million - $12.9 Million
-401,743 Reduced 20.13%
1,594,153 $50.7 Million
Q3 2020

Nov 16, 2020

BUY
$17.61 - $31.86 $31.8 Million - $57.6 Million
1,808,241 Added 963.6%
1,995,896 $51.2 Million
Q2 2020

Aug 14, 2020

SELL
$14.35 - $26.64 $3.85 Million - $7.15 Million
-268,478 Reduced 58.86%
187,655 $4.82 Million
Q1 2020

May 14, 2020

BUY
$12.31 - $33.12 $2.42 Million - $6.5 Million
196,279 Added 75.53%
456,133 $7.01 Million
Q4 2019

Feb 14, 2020

SELL
$7.26 - $38.49 $7.09 Million - $37.6 Million
-977,114 Reduced 78.99%
259,854 $8.92 Million
Q3 2019

Nov 14, 2019

BUY
$7.47 - $14.03 $8.23 Million - $15.5 Million
1,101,616 Added 813.89%
1,236,968 $9.24 Million
Q2 2019

Aug 14, 2019

SELL
$10.65 - $14.29 $6.15 Million - $8.25 Million
-577,306 Reduced 81.01%
135,352 $1.76 Million
Q1 2019

May 14, 2019

SELL
$10.9 - $14.09 $2.32 Million - $3 Million
-212,847 Reduced 23.0%
712,658 $8.68 Million
Q4 2018

Feb 14, 2019

BUY
$10.36 - $20.96 $3.95 Million - $8 Million
381,508 Added 70.13%
925,505 $10.5 Million
Q3 2018

Nov 14, 2018

SELL
$17.77 - $22.9 $7.22 Million - $9.31 Million
-406,508 Reduced 42.77%
543,997 $11.8 Million
Q2 2018

Aug 14, 2018

BUY
$17.33 - $23.4 $6.53 Million - $8.81 Million
376,537 Added 65.6%
950,505 $16.8 Million
Q1 2018

May 15, 2018

SELL
$15.16 - $25.49 $13.4 Million - $22.5 Million
-880,976 Reduced 60.55%
573,968 $12.1 Million
Q4 2017

Feb 14, 2018

BUY
$14.27 - $16.79 $1.03 Million - $1.21 Million
71,980 Added 5.2%
1,454,944 $21.1 Million
Q3 2017

Nov 14, 2017

BUY
$10.77 - $22.1 $14.9 Million - $30.6 Million
1,382,964
1,382,964 $21.8 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.12B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.